Control of parasitic diseases: a complementary role for vaccines and drugs.
This paper seeks to substantiate its title by discussion of three key questions: why are we attempting to develop parasite vaccines? Will we be successful? If we are, will there still be a need for chemotherapy? It concludes that: parasite vaccines are likely to be safer, cheaper and more efficacious as prophylactics than antiparasite drugs; in time vaccines will be developed for some but not all human parasitic diseases; at least in the short and medium term, drugs will be needed for those already infected and for those for whom, for whatever reason, a vaccination strategy fails.
Gutteridge
W E
WE
Wellcome Research Laboratories, Beckenham, U.K.
D000818:Animals; D000871:Anthelmintics / Q000627:therapeutic use; D000981:Antiprotozoal Agents / Q000627:therapeutic use; D006801:Humans; D007167:Immunotherapy; D010272:Parasitic Diseases / Q000188:drug therapy / Q000517:prevention & control*; D014614:Vaccines, Synthetic / Q000276:immunology*
D000871:Anthelmintics; D000981:Antiprotozoal Agents; D014614:Vaccines, Synthetic